Selinexor
- Generic Name
- Selinexor
- Brand Names
- Xpovio 100 Mg Once Weekly Carton, Nexpovio
- Drug Type
- Small Molecule
- Chemical Formula
- C17H11F6N7O
- CAS Number
- 1393477-72-9
- Unique Ingredient Identifier
- 31TZ62FO8F
- Background
Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. Selinexor, in combination with bortezomib and dexamethasone, is currently approved for the treatment of multiple myeloma, a type of cancer formed from antibody-producing plasma cells. This condition is typically treated with high dose bortezomib and dexamethasone chemothe...
- Indication
Selinexor is indicated in combination with bortezomib and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. Selinexor is also indicated in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma in adult patients who have received at least four prior therapi...
- Associated Conditions
- Multiple Myeloma (MM), Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsed Diffuse large B-cell lymphoma NOS
- Associated Therapies
- -
A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH )
- First Posted Date
- 2021-08-10
- Last Posted Date
- 2021-08-10
- Lead Sponsor
- Qi Zhou
- Target Recruit Count
- 96
- Registration Number
- NCT04998760
- Locations
- 🇨🇳
Chongqing Cancer Hospital, Chongqing, Chongqing, China
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease
- Conditions
- Interventions
- First Posted Date
- 2021-07-30
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Weill Medical College of Cornell University
- Registration Number
- NCT04984330
- Locations
- 🇺🇸
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM
- Conditions
- Interventions
- First Posted Date
- 2021-06-28
- Last Posted Date
- 2023-02-27
- Lead Sponsor
- Juan Du
- Target Recruit Count
- 90
- Registration Number
- NCT04941937
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 18
- Registration Number
- NCT04925193
- Locations
- 🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2021-05-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 42
- Registration Number
- NCT04898894
- Locations
- 🇺🇸
Childrens Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Rady Children's Hospital-San Diego, San Diego, California, United States
Selinexor in Combination With Thalidomide and Dexamethasone in RRMM
- Conditions
- Interventions
- First Posted Date
- 2021-05-18
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Li Zheng
- Target Recruit Count
- 48
- Registration Number
- NCT04891744
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
- First Posted Date
- 2021-04-23
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Mamta Parikh
- Target Recruit Count
- 12
- Registration Number
- NCT04856189
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations
- Conditions
- Interventions
- First Posted Date
- 2021-04-22
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 13
- Registration Number
- NCT04854434
- Locations
- 🇺🇸
Christiana Care Health Services, Christiana Hospital, Newark, Delaware, United States
🇺🇸BRCR Global, Plantation, Florida, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-04-13
- Last Posted Date
- 2023-10-25
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 4
- Registration Number
- NCT04843579
- Locations
- 🇺🇸
Weill Cornell Medicine - Multiple Myeloma Center, New York, New York, United States
🇺🇸NewYork-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients
- Conditions
- Interventions
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 56
- Registration Number
- NCT04811196
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.